Development of an adalimumab biosimilar and joint commercialization partnership in China
A theme involving partnership development and commercialization of the adalimumab biosimilar GBS-005 using manufacturing process and comparative data, culminating in the dissolution of a joint commercialization partnership in China.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.